Mutagenic assessment of olmesartan cilexetil by bacterial mutation assay

Ji Won Kim1, Ilyoung Ahn2, Sung Ha Ryu3

  • 1Department of Pharmacology, CKD Research Institute, Yongin, Korea.

Toxicological Research
|January 4, 2014
PubMed

Insights

Olmesartan cilexetil, an antihypertensive drug, was evaluated for mutagenicity. The drug demonstrated no mutagenic potential in bacterial reverse mutation tests using Salmonella typhimurium and Escherichia coli.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Hypertension is a prevalent health issue linked to cardiovascular and renal complications.
  • Olmesartan cilexetil is an angiotensin II receptor antagonist used for hypertension treatment.

Purpose of the Study:

  • To assess the mutagenicity of olmesartan cilexetil.
  • Evaluate potential DNA damage induced by the drug.

Main Methods:

  • Bacterial reverse mutation assay (Ames test).
  • Utilized Salmonella typhimurium strains (TA100, TA1535, TA98, TA1537) and Escherichia coli (WP2 uvrA).
  • Tested olmesartan cilexetil at concentrations ranging from 0 to 5000 μg/plate, with and without metabolic activation (S9 mix).

Main Results:

  • Olmesartan cilexetil tested negative for mutagenicity in all bacterial strains.
  • No reverse mutations were observed in Salmonella typhimurium or Escherichia coli.
  • Results were consistent with and without the presence of a metabolic activation system.

Conclusions:

  • Olmesartan cilexetil does not induce bacterial reverse mutations.
  • The drug is non-mutagenic in the bacterial reverse mutation test.
  • Supports the safety profile of olmesartan cilexetil regarding genotoxicity.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
In vitro Mutagenesis01:16

In vitro Mutagenesis

4.9K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.8K
Mutations in Microorganisms01:18

Mutations in Microorganisms

Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
1.2K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.4K